Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Curis Announces Additional Data from TakeAim Leukemia Study
Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... [Yahoo! Finance]
Curis Provides Third Quarter 2024 Business Update [Yahoo! Finance]